In this controlled study, we found that symptoms of AMS in older children and adolescents were relatively mild and resolved rapidly without treatment. We suggest that children planning to ascend rapidly to 3500 m may not need AMS prophylaxis.
METHODS

Study Group
Our study group consisted of 48 healthy Swiss children and adolescents (age: mean Ϯ SD: 13.7 Ϯ 0.3 years; range: 10 -17 years; 20 girls and 28 boys). All except 2 (who lived at 1100 m) were living at altitudes of Ͻ800 m. None of the participants had slept at altitudes of Ͼ1500 m in the 2 months preceding the study, none had ever spent a night at altitudes of Ͼ2000 m, and none was taking any medication at the time of the study. The experimental protocol was approved by the institutional review board on human investigation of the Centre Hospitalier Universitaire Vaudois. All parents provided written informed consent.
The participants ascended to the high-altitude research station with a 2.5-hour train ride that took them from 568 m to an altitude of 3450 m. They then spent 2 days and 2 nights at the laboratory. All participants received the same diet, and care was taken to ensure adequate fluid intake. On the day of arrival, the participants rested quietly and visited the research station and the adjacent installations. In the afternoon of the second day, all participants made an easy 2-to 2.5-hour walk to the Mö nchsjoch hut located at 3650 m. On the morning before descent, the subjects had no particular physical activity. The presence of AMS was evaluated 6, 18, and 42 hours after arrival at the high-altitude research laboratory.
Symptoms of AMS
On the evening of the day of arrival and on the 2 following mornings, symptoms of AMS were assessed with a French version of the Lake Louise self-assessment questionnaire, 7 under the supervision of a trained examiner. Briefly, for each of the 5 items (headache, gastrointestinal symptoms, fatigue, dizziness, and sleep disturbance), the participants noted a score between 0 and 3, with 0 indicating the absence of the symptom, 1, mild symptoms, 2, moderate symptoms, and 3, severe incapacitating symptoms. For children Ͻ12 years of age, a verbally adapted version of the score was used (Lake Louise age-adjusted symptom score). Clinical symptoms (change in mental status, ataxia, and the presence of edema) were assessed by one of us (Dr Bloch) immediately after completion of the questionnaire. Participants were considered suffering from AMS if they were experiencing headache and scored Ն3 on the self-assessment questionnaire (the maximal score for the questionnaire being 15).
Statistical Analyses
Statistical analyses were performed by using the paired, 1-tailed, Student's t test and the McNemar test. Data are expressed as mean Ϯ SD. A P value of Ͻ.05 was considered to indicate statistical significance.
RESULTS
All subjects completed the daily questionnaires (Table  1 ). Figure 1 shows that the majority of cases of AMS (66%) developed during the first few hours at high altitude. On the evening of the day of arrival, 12 (25%) of the 48 subjects suffered from headache and had symptom scores of Ն3 (range: 3-7). Over the subsequent 36 hours at high altitude, the prevalence of AMS decreased progressively and significantly (P Ͻ .05). On the morning of day 2, AMS had resolved for 7 of the 12 participants who suffered from AMS on the evening of the first day, it persisted for 5 of those participants, and it developed in 5 new subjects; therefore, 10 (21%) of the 48 subjects met the criteria for AMS (range of scores: 3-7). On the morning of day 3, AMS had disappeared for all except 3 subjects, and it developed in 1 new subject; therefore, only 4 subjects (8%) still had symptoms of AMS (range of scores: 3-5). The overall prevalence of AMS was 37.5%, and rates were similar for boys and girls; 7 (35%) of the 20 girls and 11 (39%) of the 28 boys had an AMS score of Ն3 on Ն1 occasion. Independent of whether AMS was present, fatigue (day 1) and fatigue together with sleep disturbances (days 2 and 3) were the leading complaints of the participants.
Among the subjects who suffered from AMS, the disease was relatively mild; the mean scores were 4.0 Ϯ 1.2 on day 1, 5.0 Ϯ 1.5 on day 2, and 3.7 Ϯ 1.0 on day 3. Only 1 of the 48 subjects scored 3 (severe incapacitating symptoms) on 1 of the items of the questionnaire. Finally, 5 subjects suffering from AMS were given a single dose of paracetamol for headache. The symptoms responded well to this symptomatic treatment. In the clinical assessment part of the Lake Louise scoring system, the signs also were mild and decreased significantly during the stay; the mean score was 0.3 Ϯ 0.6 (range: 0 -2) on day 1, 0.1 Ϯ 0.4 (range: 0 -1) on day 2, and 0.1 Ϯ 0.4 (range: 0 -1) on day 3 (P Ͻ .05, day 1 versus day 3).
DISCUSSION
With steadily increasing numbers of children and adolescents arriving by modern transportation systems at tourist destinations located at altitudes comparable to the one used in our study, it becomes important to have reliable data on the prevalence, incidence, and time course of AMS in this age group. Here we show that, in healthy nonacclimatized children and adolescents who were brought rapidly to 3450 m, the overall prevalence of AMS during the first 3 days at this altitude was 37.5%. Moreover, the prevalence decreased at each measurement, the symptoms were relatively mild, and the majority of cases resolved without treatment. These data indicate that, for children and adolescents with no previous high-altitude experience, the clinical manifestations of AMS are benign and the time course is brief.
Two thirds of the cases of AMS developed during the first few hours at high altitude. The prevalence of AMS was maximal on the evening of the day of arrival and then decreased progressively during the next 2 days at high altitude. Among those who were sick, the Lake Louise scores represented mild illness and the symptoms responded well to symptomatic treatment. None of the subjects needed to be evacuated to a lower altitude or experienced progression of AMS to high- altitude cerebral edema, the most dangerous complication of AMS. None of the subjects developed highaltitude pulmonary edema. The trend for higher AMS scores on day 2 than on day 1 was related to the fact that, on day 2, insomnia contributed to the symptom scores; this symptom did not come into account on day 1 because the subjects had spent the night at home. Insomnia was related to altitude rather than sleeping in a dormitory setting, because the subjects slept in small bedrooms. Consistent with the rather low scores on the self-assessment questionnaire, the scores for the clinical assessment part of the Lake Louise scoring system also were low. This finding suggests that, for adolescents suffering from mild to moderate AMS, clinical evaluation does not seem to provide important additional information.
The prevalence of AMS among adolescents in the present study, although still representing a significant burden of disease, was considerably lower than the rate (84%) reported for an adult population after arrival by airborne transportation at an altitude that was comparable to the one in the present study. 2 The rate was similar to that reported for an adult population studied at much lower altitude. 8 This finding might suggest that young age does not represent a risk factor for AMS. The prevalence of AMS did not differ between female and male participants, which suggests that gender does not play a role for adolescents. As in adults, physical effort may represent a risk factor for AMS in children and adolescents. One of the strengths of the present study was that physical effort was highly standardized, with only mild physical effort on the day of arrival and moderate effort on the second day. This amount of physical effort may be quite comparable to that of children and adolescents arriving at high-altitude tourist destinations after rapid ascent with mechanical transportation. Therefore, the data on the prevalence, clinical manifestations, and time course of AMS in our controlled study probably also apply to this type of pediatric population.
For adults planning rapid ascent to high altitudes, current guidelines propose prophylaxis for AMS with 
FIGURE 1
Total and day-to-day prevalence of AMS after rapid ascent by train to 3450 m among 48 healthy nonacclimatized children. AMS was assessed 6 hours after arrival (day 1) and on the morning of the next 2 days. a P Ͻ .05, day 1 versus day 3. drugs that may have significant adverse effects. 1 On the basis of the present findings, we suggest that, for children and adolescents with no history of moderate/severe AMS who plan to ascend rapidly to the study altitude, pharmacologic prophylaxis for AMS may not be needed and the use of pharmacologic agents should be restricted to the treatment of symptoms (mainly headache) if they appear.
ILL EFFECTS LIKELY NOT TIED TO GARDASIL
"Reports of serious adverse events and deaths in young girls and women following administration with Merck & Co.s Gardasil are likely not related to the cervical-cancer vaccine, federal health officials said Wednesday. A study looked at 375 000 doses of the vaccine from August 20, 2006, to July 20, 2008, in girls and women ages 9 to 26. 'Based on all of the information we have today, CDC and FDA have determined that the HPV vaccine is safe to use and effective in preventing 4 types of HPV,' the CDC said."
